The Pfizer-BioNTech vaccine and another developed by China National Pharmaceutical Group (Sinopharm) are being made available to all employees in the United Arab Emirates, parent company Emirates Group said.
Civic agency Bruhat Bengaluru Mahanagara Palike (BBMP) has identified 760 Covid-19 vaccination sites to inoculate 150,000 healthcare workers who have registered on the Co-Win portal and the city administration hopes to complete the immunisation of health personnel in a week.
“The first batch of 254,500 doses of Covishield and 20,000 doses of Bharat Biotech’s Covaxin have reached Delhi so far,” a government official said. “More batches will follow.”
According to official sources, the flight carrying the vaccines landed at the Kempegowda international airport here.
"Any new manufacturing process is going to have challenges, it's lumpy and bumpy, (then) it gets better, it stabilises and improves going forward."
This is one of the first studies that link vaccination and a drop in infection rates. The study analysed data on Covid-19 infection and hospitalisation of more than 50,000 people over the age of 60 who received the first dose of vaccine between December 19 and 24, 2020.
The drugmaker said Monday that it will focus instead on studying two possible treatments for the virus that also have yet to be approved by regulators. The company said its potential vaccines were well tolerated by patients, but they generated an inferior immune system response compared with other vaccines.
Pfizer was the first company to seek emergency-use authorisation (EUA) for a COVID-19 vaccine in India, but the government this month approved two much cheaper shots - one from Oxford University/AstraZeneca and another developed at home by Bharat Biotech with the Indian Council of Medical Research.
A special Air India flight carrying the Oxford-AstraZeneca COVID-19 vaccine co-manufactured by Serum Institute of India reached the Hazrat Shahjalal International Airport earlier in the day to be initially stored at a warehouse of private Beximco Pharmaceuticals Ltd ahead of their planned countrywide distribution.
The government has given a go-ahead to a local pharmaceutical company for the import and distribution of the Russian-developed Sputnik V, the Dawn newspaper quoted an official as saying.
Developed by Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology, the indigenous vaccine was granted emergency use authorisation in 'clinical trial mode' by the Indian government this week.
In a statement, the ministry said in the last 24 hours, 3,47,058 people were vaccinated in 6,241 sessions and 24,408 such sessions have been conducted across the country so far.
"It is expected that there may be requirements from other countries to present vaccine documentation upon entry. A Danish vaccine passport can be used here," the Health Ministry said in an emailed statement on Friday.
"The supply of COVID-19 vaccine will not be affected due to the fire. No actual vaccine was being made at that facility. We were lucky that the incident happened in a different building," Poonawalla said while addressing a press conference.
On January 16th, 2021, the Prime Minister of India virtually launched the world’s largest COVID-19 vaccination drive, with healthcare workers in the country as the first to be inoculated with one of the two COVID-19 vaccines – ‘Covishield’ developed by Oxford-AstraZeneca via Serum Institute of India (SII), and ‘Covaxin’ developed by Bharat Biotech and Indian Council of Medical Research (ICMR).
The research by the 1928 Institute, a platform created to research and reflect the views of British Indians as the UK's largest ethnic minority group, follows concerns about a lower uptake of COVID-19 jabs among Britain's ethnic minority populations and is calling on the authorities to fund a clear and concerted public health campaign.
"Study results have demonstrated the effectiveness of the vaccine in triggering a strong antibody response against the virus, its safety for use, and its compliance with international safety and effectiveness standards," the statement said.
Without any studies, vaccine doses should not be mixed.
This comes as Biden became the 46th US president on Wednesday and has laid out a goal of delivering 100 million Covid-19 vaccine doses within his first 100 days in office.
Prime Minister Narendra Modi had last week said Aadhaar would be used to identify people for the vaccination and ensure that they get the second of the two-dose vaccines. 4.5 million people took the unique ID in December and another 2.9 million already this month.
COVAX, a global scheme co-led by the WHO, wants to deliver at least 2 billion COVID-19 doses across the world this year, with at least 1.3 billion going to poorer countries.
"Negotiations are underway with an Indian manufacturer, Serum Institute, which can produce the American Novovax vaccine and has the ability to produce the AstraZeneca vaccine at the moment," Interfax quoted Ihor Ivashchenko as saying.
The COVAX scheme - led by the World Health Organization and GAVI vaccine alliance - is due to start rolling out vaccines to poor and middle-income countries in February, with 2 of 3 billion doses expected to be delivered this year.
Once children start going to the school regularly and they contract the COVID-19 infection, they will not have much problem but if they bring it home they can spread it to their parents or grandparents, the chief of the premier Delhi-based All India Institute of Medical Sciences (AIIMS) said.
There had been internal discussions within the ministry previously on whether a consent form would need to be signed by those who get the vaccine. Chhattisgarh health minister TS Singh Deo confirmed the vaccine would be voluntary.
While the coronavirus vaccine has been approved by many countries all over the world, Somalia is one of the few places where the pandemic has not been taken as seriously and that the repercussions has been worse than anyone knows.
According to Khetrapal, the use of vaccine in "priortised population" as well as implementation of other public health measures will be important in reducing the impact of the pandemic.
Regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
The immunisation drive in Delhi was formally kicked off on Saturday by Chief Minister Arvind Kejriwal from the LNJP Hospital, the state-run facility which offered yeoman service during the pandemic last year.
In the first phase, government and private sector health workers, medical students and Asha and Anganwadi workers would be among those who would receive the vaccine and so far, 3.13 lakh people have registered for the same, health department sources here said.
While Facebook has banned anti-vaccine groups, other platforms such as Twitter and WhatsApp are fuelling vaccine rumours and fear mongering. One of the bizarre conspiracy theories doing the rounds is that billionaire Bill Gates is funding some vaccine manufacturers because he wants to reduce population growth!
"Guru Teg Bahadur Hospital, Shahdara, Urban Primary Health Centre, Daryaganj, and Venkateshwar Hospital, Dwarka, are the three sites in Delhi which have been selected for the dry run of the roll out of COVID-19 vaccine in the national capital," a senior official said here on Saturday.
The UAE, made of up seven emirates, is offering all residents and citizens free of charge a vaccine manufactured by Chinese state-backed pharmaceutical giant Sinopharm.
Health workers faced some technical glitches while uploading data on the app about beneficiaries receiving the vaccine in some sites, as the application was reported to have slowed down.
Amid concerns expressed by some over the emergency-use clearance given to Bharat Biotech's Covaxin, Modi interacted virtually with healthcare workers of his Lok Sabha constituency Varanasi.
Haryana: Agitating farmers try to disrupt COVID-19 vaccination driveHaryana: Agitating farmers try to disrupt COVID-19 vaccination drive
WATCH | AIIMS Director Dr Randeep Guleria receives COVID-19 vaccine shot at AIIMS, Delhi.Delhi: AIIMS Director Dr. Randeep Guleria receives Covid-19 vaccine
"We have registered our interest to seek vaccines for our employees, in accordance with the priorities and sequence to be specified by the government," a Mahindra Group spokesperson said in a statement.
The company has the infrastructure and capabilities to handle as many charters as required, at its facility and ensure a quick 'turnaround time', it said in a release.
“At this stage in India, when ‘R0’ has come down to below one in all states then the epidemic in India is self-limiting in that sense...so, if it is self-limiting, then should we be financing it (Covid-19 vaccine)?” Indu Bhushan, CEO of Ayushman Bharat scheme, said at a webinar on Tuesday.
Administering Bharat Biotech's COVAXIN, a move cheered by nationalist politicians, has worried some health experts who consider it rushed, as the vaccine has only limited, "clinical-trial mode" approval. In addition to efficacy concerns, the close monitoring required for its use will be a massive challenge in a country of 1.35 billion people.
Dr. Anthony Fauci, the top U.S. infectious disease expert, said data coming from Britain indicates the vaccines still will block the virus. But the U.S. also will do tests to be sure.
A new variant of the virus which is highly transmissible is surging across UK.
Serum Institute vaccines were being transported to Delhi, Kolkata, Chennai, Guwahati, Shillong, Hyderabad, Ahmedabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow and Chandigarh, Union aviation minister Hardeep Singh Puri tweeted.
The European Union gave approval on Dec. 21 for the COVID-19 vaccine developed by Pfizer Inc and BioNTech SE, the latest regulatory go-ahead for the shot, while the United States authorised Moderna Inc's vaccine on Dec. 19, the second for the country and the first for the company worldwide.
Addressing a press briefing, Union Health Secretary Rajesh Bhushan said Zydus Cadila, Sputnik V, Biological E and Gennova are other vaccines also in the pipeline which are in advanced clinical trials in India.
Switzerland has been a second-wave coronavirus hotspot, with infections totalling some 500,000 and deaths rising by dozens daily to more than 7,500.
In the second phase, field staff engaged in carrying out Covid control programme would be vaccinated and it would cover those from police, revenue and local administration departments.
Civil Aviation Minister Hardeep Singh Puri said four airlines will operate nine flights to transport 56.5 lakh doses of COVID-19 vaccine from Pune to 13 cities across the country on Tuesday.
The first consignment of over 10.5 lakh vials of COVID-19 vaccines will be reaching Kolkata from Pune on Tuesday, a senior official of the state health department said.
COVID-19 vaccination sessions held in only six states today, 2.24 lakh received jab so far says Health Ministry
COVID-19 vaccination drive: In 553 sessions, a total of 17,072 beneficiaries were vaccinated today. A total of 2,24,301 beneficiaries vaccinated so far: Health MinistryCOVID-19 vaccination sessions held in only six states today, 2.24 lakh received jab so far says Health Ministry
Co-developed by the University of Oxford and British-Swedish company AstraZeneca and known as Covishield in India, the vaccine was the first on which a scientific study was published based on Phase 3 clinical trials.
New Delhi: As India commences the world’s largest COVID-19 vaccination drive on Saturday (January 16), the Ministry of Health and Family Welfare (MoHFW) took to Twitter to quell people’s doubts and concerns regarding the vaccination program, vaccine rollout, eligibility etc.Dr. Harsh Vardhan answers all queries as India kicks off world's largest COVID-19 vaccination drive
China in late December approved its first vaccine for general public use. Three vaccines had already been given to limited groups at high risk of infection, including medical workers, through an emergency-use program.
Last month, all four bank officer unions demanded for inclusion of bankers as frontline COVID-19 warriors so that they can be administered the vaccine on a priority basis, given their importance in keeping wheels of the economy running.
The EU commission later detailed in a statement that the Commission has offered to member states to purchase an additional 200 million doses of the vaccine, with the option to acquire another 100 million doses.
Further testing has been suspended until the cause for the weak immunogenicity in the Hamburg trial involving 30 volunteers has been established, UKE said in a statement, adding that the vaccine was well tolerated.
UAE Team Emirates said Friday that 27 riders and 32 staff members have had a vaccine developed by Sinopharm CNBG out of China and approved by the United Arab Emirates' Ministry of Health & Prevention.
"With the vaccination against SARS-CoV-2 at our doorsteps, it is worth remembering that indigenous vaccines have been developed after the tireless efforts of Indian scientists in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV)," the doctors' body said.
The dashboard provides a regularly updated overview of the global research and development pipeline, the projected production capacity, publicly announced bilateral and multilateral supply agreements, as well as reported price points, Xinhua news agency quoted the Unicef as saying in a statement on Monday.
The Leader of Opposition in the assembly said the MVA government should seek the Centre's help to provide free doses to the poor and middle-class families in the state.
The WHO's Hans Kluge's comments come as some countries including Britain are seeking to counter low vaccine supplies by extending the gap between first and second doses to up to 12 weeks, and by considering lower volume doses of some shots.
CureVac, based in the German city of Tuebingen, said last month that it expects first results by the end of March from its phase 3 clinical study of the mRNA-based vaccine candidate called CVnCoV.
Faced with surging pandemic and new, more transmissible coronavirus variants, some countries are hoping to broaden immunisation by giving some protection to as many people as possible with a first dose, and delaying second doses.
The meeting of the European Medicines Agency's human medicines committee (CHMP) comes amid high rates of infections in many EU countries and strong criticism of the slow pace of vaccinations across the region of some 450 million people.
Authorities have readied some 29,000 cold storage facilities across the country and large scale vaccination dry-runs have been conducted in 125 districts encompassing all states, federal health secretary Rajesh Bhushan said on Tuesday.
The bloc, with a population of nearly 450 million, has already booked a total of almost 2.3 billion doses from six vaccine makers. Most vaccines require two doses, and only two vaccines have so far been authorised for use in the EU. U.S. biotech firm Moderna produces one of the two shots approved by the EU - the other being from U.S. drugmaker Pfizer and its German partner BioNTech - and has already signed a contract with the bloc to supply 160 million doses.
Dry runs to be carried out across Uttar Pradesh today in light of the DCGI approval given to 2 Covid-19 vaccines – Covishield and Covaxin. Dry run for Covid-19 vaccination across Uttar Pradesh today
Moderna has received authorization for its COVID-19 vaccine in the United States and Canada and additional authorizations are currently under review in the European Union, Singapore, Switzerland and the United Kingdom.
Senior officials have been discussing the terms of the deal with the Serum Institute for weeks, hoping to bring down prices below $3 per shot, one of the sources said. Serum chief executive Adar Poonawalla had said in November the vaccine would be priced at about Rs 1,000 per dose for the private market in India and would cost the government about Rs 250 per dose.
Drugmaker Pfizer Inc said on Friday it had applied for approval in Japan for its COVID-19 vaccine, which is already being administered in the United Kingdom and the United States.
India's drug regulator Drugs Controller General of India (DCGI) on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
India's drugs regulator on Sunday approved Oxford COVID-19 vaccine Covishield, manufactured by the Serum Institute, and indigenously developed Covaxin of Bharat Biotech for restricted emergency use in the country, paving the way for a massive inoculation drive.
NEW DELHI:Delhi Health Minister Satyendar Jain on Sunday said the city government has finalised 89 sites to roll out the COVID-19 vaccination drive in the national capital from January 16.COVID-19 vaccine roll out: Delhi govt finalises 89 sites, says Satyendar Jain
State health ministers are holding review meetings and onsite inspections of vaccination centres as they expect the vaccine doses to arrive over the next week and the vaccination drive to begin around January 14.
A number of medical experts and public health activists have raised concerns over grant of emergency approval to Covid-19 vaccines of Bharat Biotech and Serum Institute of India without proper efficacy data, and demanded to know on what basis these
India has approved emergency use of two vaccines for coronavirus on Sunday. Developed by AstraZeneca-Oxford University and India's Bharat Biotech, the approval is set to pave the way for one of the biggest vaccination drives.
"The Covaxin has not yet had Phase 3 trials. Approval was premature and could be dangerous. @drharshvardhanshould please clarify. Its use should be avoided till full trials are over. India can start with the AstraZeneca vaccine in the meantime," Tharoor tweeted.
A dry run for COVID-19 vaccine administration was conducted at Urban Health Training Centre, Srinagar on Saturday. A total of 25 beneficiaries selected from Co-WIN platform participated during the mock drive. According to Union Health Ministry, the objective of the dry run for COVID-19 vaccine introduction is to assess operational feasibility in the use of COVID Vaccine Intelligence Network (Co-WIN) application in the field environment, to test the linkages between planning and implementation and to identify the challenges and guide the way forward prior to actual implementation. This is also expected to give confidence to program managers at various levels, it said. (Text: ANI)COVID-19 vaccine dry run held across Jammu & Kashmir
The state Health department observed January 25 as "COVID-19 Vaccination Day", with vaccine shots being given to 33,215 healthcare workers, the officials said.
Under the nationwide mega vaccination drive launched on January 16, a total of 4,319 (53 per cent) health workers against a target of 8,117 were administered the shots at 81 centres across the city on day one.
The dry run was conducted in Ganesh Das MCH Hospital, NEIGRIHMS Hospital, Rynjah State Dispensary, Nazareth Hospital and Holy Cross Hospital where a total of 129 persons were mobilized for the dry run.
Specific teams were formed for various tasks by the district administrations and activities like uploading of dummy beneficiary data, session site creation, vaccine allocation, communicating vaccination details to beneficiaries and vaccinators, and beneficiary mobilisation etc are being carried out.
After closer review of the data related to allergic reactions, the US FDA recommended that the mRNA vaccines, based on the genetic material of the novel coronavirus, be withheld only from individuals with a history of severe allergic reactions to any component of the COVID-19 vaccine.
"At least 75 people are participating in the programme at three centres. They have been asked to register their names for the vaccination mock drill. Their health condition will be observed for at least 30 minutes after completion of the exercise," the official said.
With the objective to gear up for the roll-out of COVID-19 vaccine across the country, the dry run will be conducted by all the states and UT governments from Saturday. The activity is proposed to be conducted in all state capitals in at least 3 session sites. Some states will also include districts that are situated in difficult terrain/have poor logistical support. Maharashtra and Kerala are likely to schedule the dry run in major cities other than their capital. Watch now. (Text: ANI)India-wide COVID-19 vaccine dry run starts today
Reports of possible allergic reactions to the COVID-19 vaccines produced by Pfizer-BioNTech and Moderna, both recently approved for emergency use by the US Food and Drug Administration (FDA), have raised public concern. A team of experts led by allergists at Massachusetts General Hospital (MGH) has now examined all relevant information to offer reassurance that the vaccines can be administered safely even to people with food or medication allergies. Watch now. (Text: ANI)Study offers reassurance regarding potential allergic reactions to COVID-19 vaccines
Five front-line workers in Ontario were among the first Canadians to receive the vaccine at one of Toronto's hospitals. Two nurses and three other workers at the Rekai Centre nursing home received the vaccine.
PM exhorts youths to defeat 'network of lies and rumours' on COVID-19 vaccination with right information
The prime minister said the youths should now step forward to assist in the COVID-19 vaccination programme by providing the right information to the people.
The wealthy Gulf nation is one of the first countries to start widespread inoculation, after Britain became the first to roll out a campaign using a vaccine by US pharmaceutical giant Pfizer and its German partner BioNTech.
"We would have liked to have seen it run smoothly and have 20 million doses into people today by the end of 2020, which was the projection," Fauci said during an appearance on "Today", as quoted by The Hill and added, "Obviously, it didn't happen, and that's disappointing."
The first wave of shipments is going to health care workers and nursing home residents. Officials say vaccines should be available to everyone by the middle of next year.
The Sinopharm vaccine has been approved for emergency use in a few countries and the company is still conducting late-stage clinical trials in 10 countries. Morocco is gearing up for an ambitious COVID-19 vaccination program, aiming to vaccinate 80% of its adults in an operation starting this month that's relying initially on the Sinopharm vaccine.
The UK on Wednesday approved a cheaper and easy-to-handle COVID-19 vaccine developed by scientists at Oxford University and produced by AstraZeneca for human use, the second coronavirus vaccine to be cleared for rollout in Britain after the Pfizer/BioNTech jabs.
Front-line health workers, the Army and the police and the most vulnerable elderly will be given the vaccine as a priority, the president said, amid warnings from doctors that front-line health workers should be quickly inoculated to prevent the medical system from collapsing.
The approval comes a day after Sinopharm said its vaccine showed 79.34 per cent efficacy and a 99.52 per cent antibody-positive conversion rate in the interim results of the Phase III clinical trials.
In the last few days, India has sent consignments of domestically produced coronavirus vaccines under grant assistance to Bhutan, Maldives, Nepal, Bangladesh, Myanmar, Mauritius and Seychelles. It is also undertaking commercial supplies of the doses to a number of countries, including Saudi Arabia, South Africa, Brazil and Morocco.
India has undertaken contractual supplies of coronavirus vaccines to Saudi Arabia, South Africa, Brazil, Morocco, Bangladesh and Myanmar, the Ministry of External Affairs (MEA) said in New Delhi on Friday.
Germany expects the European Union to give rapid approval to the coronavirus vaccine developed by Oxford University and AstraZeneca that was cleared for use in Britain on Wednesday, its top vaccines official said.
Regulatory endorsement is a welcome boost for AstraZeneca and the Oxford team, which have been accused of a lack of clarity about the results from late-stage trials.of the new variant but expect that their shots will be effective against it.